An innovative, strategically focused management team with neuromuscular disease gene therapy, global drug development, and new venture development expertise.
President & Chief Executive Officer
Bruce Halpryn, Ph.D.
Secretary & Chief Operating Officer
Louise Rodino-Klapac, Ph.D.
Chief Scientific Officer
Peter Kleinhenz, MBA
Treasurer & Chief Financial Officer
Brian Price, Ph.D.
Vice President of Pharmaceutical Development